Serum M Protein

The discrete pattern reflects production by one expanded plasma-cell or B-cell clone rather than a broad mixture of immunoglobulins. Because the clone produces a homogeneous immunoglobulin or fragment, its product concentrates into a recognizable band or spike on electrophoresis. This clonal pattern is the key laboratory signal prompting further characterization.

Serum protein electrophoresis displays the abnormal product as a discrete monoclonal band or spike, making the finding visible within the serum protein pattern. Immunofixation then characterizes that finding by identifying its heavy-chain and light-chain type. Together, these methods provide both pattern recognition and more specific immunoglobulin classification.

Heavy- and light-chain typing gives a more specific description of the monoclonal product detected in serum. This characterization distinguishes the immunoglobulin or fragment produced by the expanded clone and adds information beyond the band or spike observed by electrophoresis. It therefore supports a more complete laboratory assessment of a monoclonal gammopathy.

Quantifying serum M protein helps estimate disease burden in disorders associated with monoclonal gammopathies. The measured amount provides more information than detection alone because it allows clinicians to follow the magnitude of the abnormal product. In hematology, this supports evaluation of conditions such as monoclonal gammopathy of undetermined significance, multiple myeloma, and related disorders.

Evaluation commonly uses serum protein electrophoresis to detect a discrete band or spike, followed by immunofixation to identify the product's heavy- and light-chain type. The M protein can then be quantified for clinical assessment. This sequence moves from recognizing an abnormal serum pattern to characterizing and measuring the monoclonal product.

Repeated measurements show whether the quantity of serum M protein changes over time. Those trends help assess treatment response, follow disease burden, and identify biochemical progression. A single result establishes the presence and amount of the abnormal product, whereas serial results provide the temporal context needed for monitoring monoclonal gammopathies in clinical medicine.

Serum M protein measurements support evaluation of monoclonal gammopathies, including monoclonal gammopathy of undetermined significance, multiple myeloma, and related disorders. In these settings, detection and quantification contribute to disease assessment, while serial testing helps monitor response to treatment and recognize biochemical progression. This makes the marker particularly relevant to hematology.